Core Viewpoint - The company, Kexing Pharmaceutical, is actively pursuing funding to support its new drug development and international commercialization efforts, indicating a strategic focus on growth in the biopharmaceutical sector [1] Company Overview - Kexing Pharmaceutical's latest stock price is 44.63 yuan, reflecting a 0.56% increase from the previous trading day [1] - The stock reached a high of 44.91 yuan and a low of 43.26 yuan during the trading session, with a total transaction volume of 314 million yuan and a turnover rate of 3.53% [1] - The company specializes in the research, development, production, and sales of recombinant protein drugs and microbiome preparations, with key products including recombinant human erythropoietin, recombinant human interferon α1b, and Clostridium butyricum dual live bacteria [1] Financial Activities - The company plans to apply for the registration of technology innovation bonds not exceeding 800 million yuan to support new drug research and overseas commercialization [1] - The board has approved a resolution to provide interest-free loans of up to 20 million yuan to its wholly-owned subsidiary, specifically for the upgrade of the research and development center [1] Capital Flow - On the day of reporting, the net outflow of main funds was 6.722 million yuan, with a cumulative net outflow of 78.8172 million yuan over the past five trading days [1]